PRKAA2 and fatty liver disease: These mouse models have not only confirmed the anticipated roles of AMPK signaling in metabolic ailments, such as fatty liver disease and liver cancer, but have also uncovered its involvement in non-metabolic conditions such as thrombosis (Box 2), the anti-viral response and pulmonary hypertension.